false
OasisLMS
zh-CN,zh-TW,en,fr,de,hi,ja,ko,pt,es
Catalog
Membership Special - Pituitary and Thyroid Disease ...
Clinical Advances in Pituitary Diseases
Clinical Advances in Pituitary Diseases
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Dr. Bettina Winzler presents a study on the use of glucagon-like peptide 1 receptor agonists in primary polydipsia, a condition characterized by excessive fluid intake. The study aimed to explore whether these medications could reduce fluid intake and thirst in patients with primary polydipsia. The study was a randomized, placebo-controlled, double-blind crossover trial, with participants undergoing a three-week treatment phase on either placebo or dulaglutide, a GLP-1 receptor agonist. The primary outcome measure was total fluid intake during an eight-hour evaluation visit, with secondary measures including thirst perception, reported average daily fluid intake, and urinary frequency. The results showed that patients on dulaglutide had a significant reduction in fluid intake compared to placebo, with a relative reduction of 17%. Thirst perception was also significantly reduced in patients on dulaglutide. The study suggests that GLP-1 receptor agonists may be a potential treatment option for primary polydipsia, reducing excessive fluid intake and improving thirst perception. Further research is needed to explore the optimal dosage and long-term effects of GLP-1 receptor agonists in this condition.
Keywords
glucagon-like peptide 1 receptor agonists
primary polydipsia
excessive fluid intake
fluid intake reduction
thirst perception
dulaglutide
GLP-1 receptor agonist
randomized controlled trial
placebo-controlled study
urinary frequency
×